Articles tagged with Cancer Medication
A University of Leeds investigation found that many over-the-counter herbal remedies are missing crucial safety information, despite new EU regulations. The study evaluated 68 products from various stores and pharmacies, revealing 93% were unlicensed and lacking comprehensive warnings.
Scientists at Duke University Medical Center and Johns Hopkins University discovered the most likely genetic mutations on chromosomes 1 and 19 involved in oligodendroglioma development. These genes, CIC and FUBP1, are rarely mutated in other cancers, increasing the chances for effective combination drug therapy.
Researchers at Cold Spring Harbor Laboratory identify Brd4 as a novel drug target for acute myeloid leukemia, an aggressive blood cancer. The new therapeutic agent, JQ1, shows remarkable anti-leukemia activity and minimal toxicity to non-cancerous cells.
Researchers have discovered a compound that attacks cancer cells by depriving them of glucose, a process found in most rapidly dividing cells. The team tested the compound on kidney cancer cells and found it nearly halved glucose uptake and slowed tumor growth, with minimal side effects.
A study by Andrew Weng and colleagues identifies insulin growth factor-1 (IGF-1) as a key driver of cancer growth in T cell acute lymphoblastic leukemia. Blocking the IGF-1 receptor improves survival rates in mice, suggesting a potential new treatment strategy.
Researchers found that combining tamoxifen with dasatinib reverses chemo-resistance caused by cancer-associated fibroblasts. The combination normalized glucose intake and reduced mitochondrial oxidative stress, leading to nearly 80% cell death.
A study found that one in ten elderly Medicare patients skip prescribed medication due to cost, regardless of cancer presence. Cancer survivors and non-survivors show similar rates of cost-related non-adherence, using strategies like generic medications and price comparisons.
Researchers at UCLA's Jonsson Comprehensive Cancer Center developed combination treatments to combat BRAF gene mutations in melanoma. The study identified optimal combinations of molecules to block key pathways, showing promise for extending treatment effectiveness and improving patient outcomes.
A new study found that a combination of two immunosuppressive drugs, tacrolimus and mycophenolate mofetil, led to less organ rejection and better kidney function in patients after kidney transplant. The results suggest that this regimen is the safest and most effective option for long-term success.
Researchers will study diet, weight, physical activity, and environment's impact on cancer and cancer survivorship. The goal is to reduce cancer-related deaths from obesity and improve treatments.
Tamoxifen therapy for 5 years improves survival by about a third in women with hormone-sensitive breast cancer, according to an analysis of over 20,000 patients. The treatment reduces the risk of breast cancer recurrence and death in ER-positive disease, regardless of chemotherapy use.
A high-throughput screen identified several compounds that inhibit invadopodia formation, a key step in cancer cell invasion. In contrast, another compound, paclitaxel, was found to promote invadopodia formation and cancer cell invasion.
A nationally representative survey of 1,072 primary care physicians and 1,130 oncologists found significant barriers to effective communication and coordination of care following initial cancer treatment. Optimal cancer survivorship care includes surveillance for recurrence, managing late medical effects, and psychosocial support.
The OPTIMAL trial found erlotinib significantly prolonged median progression-free survival compared to chemotherapy (13.1 months vs 4.6 months). Serious treatment-related side effects were also more common in patients receiving chemotherapy.
A large clinical trial in Latin America found a standard three-drug regimen for treating H. pylori more effective than four-drug regimens in Europe and Asia. The study, published in The Lancet, suggests that geographic variations in H. pylori resistance to antibiotics may account for the discrepancy.
Researchers developed a new mouse model to test cancer drugs by simulating gene inhibition, preventing rapid cell division in cancer cells while leaving healthy cells unaffected. The study published in Nature Communications validates the preclinical relevance and predictive value of the inducible RNAi-based mouse model.
Scientists have successfully used camel blood-derived nanobodies to target and kill cancer cells expressing specific markers. The approach involves attaching the nanobodies to nanoparticles that deliver a killer gene, preventing non-specific cell killing and improving safety.
A novel combined therapy has been developed to treat brain cancer patients with neoplastic meningitis, a devastating neurological complication. The treatment involves delivering chemotherapy directly to the brain's surfaces while draining excess spinal fluid to alleviate pressure and improve quality of life.
Scientists discovered a novel compound, piperlongumine, that selectively targets cancer cells' response to oxidative stress, inducing cell death without harming normal cells. The compound's effectiveness surpassed that of a commonly used chemotherapy drug, paclitaxel.
A recent study by UCLA found that nearly all patients with high-grade, non-invasive bladder cancer are not receiving comprehensive care recommended by the American Urology Association and National Comprehensive Cancer Network. This is critical as it can significantly minimize the likelihood of patient death from their cancer.
Researchers identified PXR as a key protein sensing xenogens, which enhances cancer characteristics in human cells. Activation of PXR leads to colon cancer growth through FGF19 induction, suggesting environmental factors may influence tumor recurrence.
The number of elderly cancer patients taking multiple medications is increasing, posing a significant risk of adverse drug reactions and interactions. Research suggests that polypharmacy is becoming more frequent in older adults due to the increasing number of drugs used to prevent or treat medical problems.
Researchers at Georgia Institute of Technology have designed a unique gel capsule structure that can co-deliver distinct drugs. The microcapsule's spatially-segregated compartments make it suitable for multi-drug encapsulation and release strategies, offering potential advantages such as synergistic effects and suppressed drug resistance.
Researchers discovered that when rats tasted fatty foods, cells in their upper gut produced endocannabinoids, triggering a surge in cell signaling that prompts overeating. The study suggests that obstructing endocannabinoid activity may curb this tendency, offering new potential treatments for obesity and related diseases.
Researchers at Salk Institute find that a short segment of p53 regulates activity in blood-forming stem cells, affecting their survival and proliferation after DNA damage. The study suggests that targeting this regulatory mechanism with drugs could reduce unwanted tissue damage from chemotherapy or radiation treatment.
Researchers at Dana-Farber Cancer Institute have discovered a new approach to make more types of tumors susceptible to PARP inhibitor treatment. By blocking the cell-cycle protein CDK1, which supports BRCA1 repair function, cancer cells become vulnerable to DNA-damage agents and ultimately die.
Researchers at UBC have developed a novel drug delivery device that can be implanted behind the eye to treat retinal damage caused by diabetes. The device uses an external magnetic field to trigger controlled release of drugs, offering improvements over existing implantable devices.
Researchers at Van Andel Research Institute have uncovered a possible explanation for the toxicity of anti-cancer antibiotics. The discovery could lead to new and improved drugs for several types of cancer, reducing side effects and improving treatment outcomes.
Research at Yale University reveals 10-20% of breast cancers classified as ER negative are actually positive, leading to under-treatment and missed opportunities for effective therapies. A new method for standardizing Estrogen Receptor measurement has been developed, which detects the receptor with higher sensitivity and reproducibility.
Researchers developed a novel approach to cancer therapy by creating a drug that inhibits the mobility of cancer-promoting proteins within cells. The treatment uses a 'glue' molecule that binds to these proteins, forcing them to the cell membrane and making cancer cells more vulnerable to chemotherapy.
Researchers will use a quantitative proteomics approach to identify biomarkers for bile duct cancer in patients infected with Opisthorchis viverrini. The study aims to develop early diagnostic tools for this deadly disease, which affects over 40 million people in Southeast Asia.
Researchers found that prostate cancer can adapt to hormone therapy by activating a survival cell signaling pathway, making it more effective. The study's findings suggest that targeting both the androgen receptor and PI3K pathways may be necessary to effectively treat these cancers.
A new study by Penn State researchers found that cancer survivors in the US spend an average of $9,300 per year on medical expenses, significantly more than those who have never had cancer. The study also revealed gender and demographic disparities in healthcare spending among cancer survivors.
Researchers have developed Cornell Dots, ultra-small particles that can light up cancer cells. The technology enables visualization during surgical treatment and shows invasive or metastatic spread to lymph nodes and distant organs.
Researchers at UCSD identified a tumor inflammation trigger common to most cancers, which can be blocked by inhibiting a single protein. This inhibition reduces primary tumor growth and halts tumor progression and metastasis in animal studies.
A combination of hypnosis and local anaesthesia during surgery has been found to reduce hospital stays and opioid drug use, improving patient comfort and aid healing. The technique has been successfully used in breast cancer and thyroidectomy procedures, with benefits extending to healthcare systems.
The new iGXT Platform combines genetically engineered mouse models with patient-derived tumor xenograft models for more accurate cancer drug testing. The partnership aims to improve treatment outcomes by identifying effective biomarkers and personalized therapy options.
The National Toxicology Program has added eight substances to the HHS Report on Carcinogens, identifying chemicals that may increase cancer risk. These include formaldehyde, a known human carcinogen linked to nasal and other cancers, and captafol, a fungicide with limited evidence of lung cancer.
A multi-site study has shown that the new drug Cabozantinib is effective in treating prostate cancer that has spread to the bone, with three-quarters of patients experiencing partial or complete tumor shrinkage. Additionally, patients showed significant improvements in bone pain and reduced need for narcotic use.
A study of over 1,000 patients with colon cancer found that 13% received unproven chemotherapy regimens, resulting in unnecessary side effects and costs totaling millions. The researchers emphasize the importance of evidence-based treatment for cancer patients to avoid harming them with ineffective therapies.
Researchers have found that people with HIV can be safely treated with cancer therapies without adverse interactions. The study, conducted by the AIDS Malignancy Consortium, explores potential interactions between highly active anti-retroviral therapy (HAART) and newer targeted cancer drugs.
A study introduced at SNM's 58th Annual Meeting found that 4D PET imaging using state-of-the-art image reconstruction and motion correction significantly improves cancer detection. This method provides clearer images, especially for small lesions, allowing for more accurate diagnosis and better treatment planning.
Researchers find that melanoma cells can develop an invasive phenotype when exposed to anti-melanoma drugs, leading to relapse. Blocking CCL2 or its upstream effectors may represent a novel therapeutic approach.
A Northwestern University study found that cancer survivors experience moderate to severe symptoms such as pain, fatigue, and disturbed sleep, often unaddressed by healthcare providers. Researchers emphasize the need for education programs and tailored interventions to manage these chronic symptoms.
A clinical trial revealed crizotinib's effectiveness in shrinking tumors and improving responses in over 60% of ALK-positive advanced non-small cell lung cancer patients. The treatment has shown dramatic benefits with minimal side effects, opening new avenues for targeted therapy.
Researchers are testing a new treatment for triple-negative breast cancer using the experimental drug entinostat, which aims to reprogram tumor cells to respond to hormone therapy. The clinical trial is evaluating the effectiveness of combining entinostat with an aromatase inhibitor in postmenopausal patients.
Researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating the combination of Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers. The therapy showed encouraging results, with 44% of patients responding to the treatment.
Researchers found that itraconazole can delay the progression of prostate cancer and reduce PSA levels, with 48.4% of patients experiencing stable or declining PSA after high-dose treatment. The antifungal also disrupted a key cancer-initiating biological pathway called Hedgehog.
Researchers are conducting a clinical trial called MANTICORE to detect and treat cardiovascular disease in breast cancer patients before treatment begins. The study aims to use special blood tests and imaging scans to identify potential cardiac risk factors.
Researchers have discovered that protein kinase C inhibitors can block kidney damage caused by the cancer drug cisplatin. This finding suggests using these inhibitors as an adjunct therapy to reduce toxicity and improve treatment outcomes.
Researchers at UT Southwestern Medical Center found that the cancer drug SAHA increases cell-signalling protein progranulin levels in cultured mouse cells and restores near-normal production in human subjects with FTD. The study suggests SAHA may be a promising first-generation treatment for familial frontotemporal dementia.
Researchers at OHSU Knight Cancer Institute discovered a gene called Src that plays a key role in kidney cancer growth. This finding could lead to more effective treatments for patients who don't respond to current therapies. The study's authors are now initiating clinical trials to test how these tumors respond to existing FDA-approve...
A personalized vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with improved response in patients with a specific biological marker. The trial's findings have the potential to usher in a new age of cancer vaccines.
A protein activated by diabetes drugs may slow cancer spread in breast tumors, and removing it increases cancer risk. Women exposed to environmental pollutants or poor diets are more likely to develop aggressive breast cancers.
Researchers developed a new test that identifies specific tumour types in ovarian cancer patients, enabling doctors to personalize treatment programmes. The test may improve survival rates by identifying aggressive forms of cancer that respond well to targeted drug treatments.
A UNC laboratory study shows that Tacrolimus, a commonly used organ transplant rejection medication, inhibits breast cancer growth by over 70 percent in pre-clinical studies. The drug works by blocking new blood vessel growth to tumors, a therapeutic strategy to inhibit tumor growth.
A four-in-one combination pill, containing aspirin and agents to lower blood pressure and cholesterol, has been shown to halve the predicted risk of heart disease and stroke. The trial tested 378 people with raised cardiovascular risk against a placebo.
A recent study by Michigan State University found that many patients struggle to take oral chemotherapy properly, leading to complications and premature death. The study highlights the need for healthcare providers to monitor and facilitate adherence through identifying barriers and implementing strategies to overcome them.
Researchers suggest 10 changes medical oncologists can make to flatten costs, maintain or improve care, and save money for future medical advances. The authors also emphasize the need for open communication between doctors and patients about end-of-life care.
A study published in Nature shows that a combination therapy of RI-BPI and Gleevec eradicates cancer in cell and animal studies, targeting the Philadelphia chromosome-positive (Ph+) form of acute lymphoblastic leukemia (ALL). This breakthrough offers new hope for improved survival rates for children with this aggressive cancer.